**Commentary**
Volume 14:01, 2024

Journal of Bioengineering & Biomedical Science

ISSN: 2155-9538 Open Access

# Dualistic Effects of PRKAR1A as a Potential Anticancer Target in Cancer Cells and Cancer-derived Stem Cells

**Gabriela Umberto***

*Department of Cell and Molecular Biology, University of Chicago, Chicago, USA*

## Introduction

Cancer is a complex disease characterized by uncontrolled cell growth and proliferation. Despite significant advancements in treatment modalities, cancer remains a major global health challenge. One promising avenue for cancer therapy is the identification and targeting of key molecular players involved in tumor progression. Protein kinase a regulatory subunit 1A has emerged as a potential target for anticancer therapy due to its dualistic effects in cancer cells and Cancer-Derived Stem Cells (CSCs). PRKAR1A, a component of the PKA holoenzyme, plays a crucial role in various cellular processes, including proliferation, differentiation, and apoptosis. Dysregulation of PRKAR1A has been implicated in the pathogenesis of several cancer types, including breast, colorectal, and pancreatic cancer. In cancer cells, PRKAR1A can act as a tumor suppressor or promoter depending on context and cellular conditions [1].

PRKAR1A exerts tumor-suppressive effects by inhibiting cell proliferation through modulation of downstream signaling pathways such as the cAMP-PKA pathway. Activation of PRKAR1A leads to the suppression of cell cycle progression and induction of cell cycle arrest. PRKAR1A enhances apoptosis in cancer cells by regulating apoptotic pathways, including the mitochondrial and death receptor-mediated pathways. Activation of PRKAR1A promotes the release of pro-apoptotic factors and sensitizes cancer cells to apoptotic stimuli. Under certain conditions, PRKAR1A may promote tumor progression by activating survival pathways such as the PI3K-AKT pathway. This activation promotes cell survival, proliferation, and resistance to apoptosis, contributing to cancer cell survival and metastasis. PRKAR1A has been implicated in the regulation of EMT, a process crucial for cancer cell invasion and metastasis. Dysregulation of PRKAR1A can promote EMT, leading to increased cancer cell motility and invasiveness [2].

## Description

Cancer-derived Stem Cells (CSCs) represent a subpopulation of cancer cells with self-renewal and differentiation capabilities, contributing to tumor initiation, progression, and therapeutic resistance. Emerging evidence suggests that PRKAR1A plays a crucial role in regulating CSC properties and tumor heterogeneity. PRKAR1A regulates CSC self-renewal by modulating key signaling pathways involved in stem cell maintenance, such as Wnt/β catenin, Notch, and Hedgehog pathways. Activation of PRKAR1A inhibits CSC self-renewal, thereby reducing tumor initiation and recurrence. PRKAR1A promotes CSC differentiation by modulating transcriptional regulators and epigenetic modifiers involved in lineage specification. Induction of CSC differentiation leads to decreased tumorigenic potential and increased sensitivity to conventional therapies [3].

Given its dualistic effects in cancer cells and CSCs, PRKAR1A represents an attractive therapeutic target for anticancer therapy. Strategies aimed at modulating PRKAR1A activity include small molecule inhibitors, gene therapy approaches, and combination therapies targeting PRKAR1A and other signaling pathways. Development of small molecule inhibitors targeting PRKAR1A activity or its downstream effectors holds promise for disrupting oncogenic signaling pathways and inhibiting tumor growth [4]. These inhibitors can be designed to selectively target PRKAR1A in cancer cells while sparing normal cells. Gene therapy strategies involving the delivery of PRKAR1A or its regulators to cancer cells or CSCs offer potential therapeutic avenues for restoring PRKAR1A function and inhibiting tumor progression. Gene editing technologies such as CRISPR/Cas9 can be utilized to precisely modulate PRKAR1A expression and activity. Combinatorial approaches targeting PRKAR1A along with other molecular targets or conventional chemotherapeutic agents can enhance therapeutic efficacy and overcome drug resistance mechanisms in cancer cells and CSCs. Rational design of combination therapies based on the specific molecular profile of individual tumors holds promise for personalized cancer treatment [5].

## Conclusion

PRKAR1A plays a dualistic role in cancer cells and CSCs, exerting tumor-suppressive or promoting effects depending on context and cellular conditions. Understanding the complex regulatory mechanisms governing PRKAR1A function in cancer biology is essential for developing effective therapeutic strategies targeting this molecule. Future research efforts focused on elucidating the precise molecular mechanisms underlying PRKAR1A-mediated anticancer effects and identifying novel therapeutic targets in cancer cells and CSCs are warranted to advance the development of precision cancer therapies.

## Acknowledgement

None.

## Conflict of Interest

None.

## References

1. Sung, Hyuna, Jacques Ferlay, Rebecca L. Siegel and Mathieu Laversanne, et al. "Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries." *CA Cancer J Clin* 71 (2021): 209-249.
2. Torre, Lindsey A, Rebecca L. Siegel, Elizabeth M. Ward and Ahmedin Jemal. "Global cancer incidence and mortality rates and trends-an update." *Cancer Epidemiol Biomarkers Prev* 25 (2016): 16-27.
3. Alieva, Maria, Jacco van Rheenen and Marike LD Broekman. "Potential impact of invasive surgical procedures on primary tumor growth and metastasis." *Clin Exp Metastasis* 35 (2018): 319-331.
4. Fang, Xiaona, Qian Yan, Shan Liu and Xin-Yuan Guan. "Cancer stem cells in hepatocellular carcinoma: Intrinsic and extrinsic molecular mechanisms in stemness regulation." *Int J Mol Sci* 23 (2022): 12327.

***Address for Correspondence:** Gabriela Umberto, Department of Cell and Molecular Biology, University of Chicago, Chicago, USA, E-mail: umberto@edu.com*



**Received:** 27 January, 2024, Manuscript No. jbbs-24-133267; **Editor Assigned:** 29 January, 2024, PreQC No. P-133267; **Reviewed:** 14 February, 2024, QC No. Q-133267; **Revised:** 19 February, 2024, Manuscript No. R-133267; **Published:** 26 February, 2024, DOI: 10.37421/2155-9538.2024.14.396

5. Phi, Lan Thi Hanh, Ita Novita Sari and Ying-Gui Yang, et al. "Cancer Stem Cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment." *Stem Cells Int* 2018 (2018).

**How to cite this article:** Umberto, Gabriela. "Dualistic Effects of PRKAR1A as a Potential Anticancer Target in Cancer Cells and Cancer-derived Stem Cells." *J Bioengineer & Biomedical Sci* 14 (2024): 396.